Business Wire

CSC Global Financial Markets Acquires PEF Services LLC; Transaction Expands Fund Services Capabilities Serving Private Capital in the U.S.

3.6.2021 16:00:00 EEST | Business Wire | Press release

Share

CSC, the world’s leading provider of business, legal, tax, and digital brand services, is pleased to announce that it has acquired PEF Services LLC (PEF), a leading provider of technology-enabled fund administration services to private capital firms and their investors, including private equity, private debt, venture capital, and U.S.-based small business investment companies (SBICs).

This strategic acquisition greatly accelerates CSC’s fund services growth plans in the U.S., adding expertise and a robust technology platform to CSC’s increasingly sophisticated solutions. The deal underscores CSC’s commitment to the growing private capital fund administration market and builds upon CSC’s other recent expansion efforts in the U.S., Europe, and Asia.

“We’re very excited to welcome Anne Anquillare and the entire PEF team to CSC,” says CSC Executive Vice President John Hebert. “Their deep expertise in fund administration complements our existing capabilities, while their commitment to service excellence aligns well with our company culture.”

U.S.-based PEF was founded in 2002 to support the unique compliance and reporting needs of SBICs. As federally licensed entities, these alternative investment vehicles have requirements that other service firms struggle to meet. PEF’s success in managing these intricate requirements allowed it to expand easily to include all types of illiquid alternative asset firms, especially those with customized needs, which aligns nicely with CSC’s passion for complex structures. PEF’s deep understanding of the complexities and customer needs in the illiquid alternative asset class has resulted in its reputation for thought leadership. CSC’s acquisition of PEF Services furthers CSC’s unwavering commitment to alternative asset managers and their investors.

In addition to PEF’s client services team, CSC will now have access to PEF’s industry-leading ViewPoint™ investor and general partner portal. Since its inception, PEF has been at the forefront of fund administration technology, providing their clients a mix of proprietary technologies and industry-standard platforms, resulting in a system that is powerful, flexible, and purpose-built for private capital fund financial reporting, investor communications, and data management.

Anne Anquillare, CFA, chief executive officer and president of PEF, joins CSC as the head of CSC U.S. Fund Services. Beth Manzi, CPA, chief operating officer of PEF, joins CSC to lead U.S. operations for fund administration. Oleg Yablonovskiy, managing director of CSC U.S. Fund Services, will move into a strategic role to drive synergies between the businesses. CSC values that PEF is a woman-led business, and these new roles reinforce CSC’s strong commitment to diversity and inclusion. PEF’s high-quality tenured team of professionals will join CSC immediately as part of the acquisition.

“As market requirements expanded, we searched for the perfect partner to enhance the exceptional fund administration services and technology solutions we provide,” says Anquillare. “CSC already has tremendous resources supporting private capital firms on a global scale and we will be a natural extension of those services. In turn, CSC recognized PEF’s reputation for having one of the most skilled and respected teams in the industry, leading-edge portal technology, and thought leadership in private capital. Both firms share a commitment in supporting private capital firms with excellent customer service, innovative technology, and investing in our people.”

About CSC

CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com.

About PEF

PEF is the new standard in providing high-value, high-touch fund administration services and technology solutions that elevate operational performance to drive and support sustainable growth. Supported by senior professionals with extensive experience in alternative investments, PEF has a nearly 20-year track record of delivering cost-effective, best-in-class solutions to funds and general partnerships, including buyout, venture, emerging managers, real estate, debt, fund of funds, co-investment, SPVs and SBICs. Additionally, the firm focuses on meeting the unique administration and data needs of limited partners investing in illiquid alternative assets. PEF’s ViewPoint™ provides clients with a purpose-built portal that delivers greater visibility and real-time access to underlying investment performance data sourced directly from the official books and records of the fund. For more information, please visit pefservices.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jeff Lyons
Public Relations Manager, CSC
(302) 636-5401 x65518
jeff.lyons@cscglobal.com
CSC News Room

Laura Hills
Senior Vice President, PEF Services
(212) 203-4667
laura.hills@pefservices.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye